NCT06067425TERMINATEDanonymous

A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia

Sponsor

Source record

Sanofi

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

SAR442501

Indication / condition

AI-normalized

Osteochondrodysplasia

Intervention

Source record

SAR442501

Related intelligence directories

Indication directory: Osteochondrodysplasia Modality directory: small molecule Target directory: SAR442501

Source & freshness

Source record

NCT ID

NCT06067425

Original source

ClinicalTrials.gov

Source last updated

Feb 25, 2025

Ingested at

Jun 20, 2026

Internal sync

Jun 20, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT06067425

Title

A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia

Sponsor

Sanofi

Status

TERMINATED

Phase

PHASE2

Condition raw

Osteochondrodysplasia

Condition normalized

Osteochondrodysplasia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

SAR442501

Target normalized

SAR442501

Interventions

SAR442501

Public preview

Source record

This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT06067425

Status

TERMINATED

Phase

PHASE2

Sponsor

Sanofi

Executive brief

Investment-Ready Snapshot

This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedFeb 25, 2025

Internal syncJun 20, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06067425

Indication

Osteochondrodysplasia

Modality

small molecule

Target

SAR442501

Intervention

SAR442501

Source record